Phase 2 Type 2 Diabetes Trial (Lancet, 2023) Study Title: Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes Links: Lancet: [thelancet.com] ClinicalTrials.gov: NCT04867785 [thelancet.com] Key Findings: 281 participants with Type 2 diabetes
183 TashiroA.MindenA.YusteR
If youre serious about longevity, immune function, or cellular health, measuring your glutathione status is one of the most powerful ways to assess how well your body is coping with internal and external stressors
Michigan, North Carolina and Rhode Island have already or may restrict coverage due to budget limits, while others debate expansion
Patients who were already comfortable on Ozempic can continue accessing it at the same cost
Be cautious about telehealth promises: If a platform promises effortless results at very low doses, ask questions